Zhitong Finance App News, Shengnuo Biotech (688117.SH) announced that US customer A signed a purchase order for peptide APIs with Shengnuo Pharmaceuticals, a wholly-owned subsidiary of the company, on February 6, 2025 and November 24, 2025, and paid a total of 39.6588 million US dollars to the company based on the purchase order. Affected by Shengnuo Pharmaceuticals being included in the US Food and Drug Administration (“FDA”) import ban list No. 66-40, the company agreed to return part of the API it had already purchased through joint negotiations with the customer, and the company also refunded the corresponding purchase price of US$249.596 million.

After the refund was made in accordance with the agreement, the company is expected to reduce its main business revenue by 163 million yuan and total profit by 99.1137 million yuan this year, and the net profit attributable to shareholders of the listed company is expected to decrease by 84.2466 million yuan. The refund does not involve adjustments to the company's accounting data for the first three quarters of 2026 and the previous year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.